Navigation Links
Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
Date:11/7/2007

lly associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to currently marketed anthracyclines.

About XYOTAX

XYOTAX(TM) (paclitaxel poliglumex) is a biologically enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
2. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
7. Haemacure Reports Third Quarter 2007 Results
8. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. MDS Reports Third Quarter 2007 Results
11. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Today, Therapy Changes released a ... The guide outlines common questions an individual may have ... common types of groups an individual can attend. , ... interventions of the therapist, but also from observing others ... says Rochelle Perper, Ph.D. and founder of Therapy Changes. ...
(Date:9/2/2014)... Recently, Top 10 Best SEO Hosting has compared ... ( http://www.justhost.com/track/seohosts ) and BlueHost are the best ... we recommend are the best web host companies ... and server speed with top-level support," a spokesman ... believe that BlueHost and JustHost are great hosting ...
(Date:9/2/2014)... TCG, a leading government technology strategy and IT ... the fastest-growing companies in America for the seventh year in ... recognized in 2013, 2012, 2011, 2010, 2009, 2008, and the ... from 2010 to 2013, ranking the company at position 3,708 ... - up 635 spots from 2013! More information is on ...
(Date:9/2/2014)... Las Vegas, NV (PRWEB) September 02, 2014 ... a leading provider of “Cloud Based” Medical Practice Business ... and a provider of Digital Cyber Security solutions for ... was recently interviewed on the trading floor of the ... Flynn. Mr. DeLaGarza stated that we are very ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The Wm. Jennings ... fair and public town hall meeting for Veterans and their ... at the outreach fair to provide Veterans with valuable healthcare ... “The town hall will provide a forum where we can ... programs.” , The outreach fair will be held 4:45 p.m. ...
Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3
... ... based on scientific evidence, including toxins such as pesticides, and provides proven natural treatments ... ... new book on ADHD by Dr. Sanford Newmark, one of America’s leading integrative pediatricians, ...
... solace in talks with partners and friends, researchers found , WEDNESDAY, ... found that it,s a good idea for men to confide to ... unhappiness -- but the same was not necessarily true for women. ... 861 people aged 57 to 85. They all had sexual partners ...
... likely to develop problem , WEDNESDAY, May 19 (HealthDay ... other similar medications, may prompt long-term hearing loss among ... 18 issue of the Archives of Otolaryngology -- ... of Alabama at Birmingham discuss evidence supporting an association ...
... ... by Health Savings Account (HSA)-eligible insurance plans, an increase of 25 percent since last ... , ... May 19, 2010 -- Ten million Americans are covered by Health Savings Account (HSA)-eligible ...
... ... , ... -- Can companies generate leads and sales from social media? That’s the number one question ... , A new report from Zuberance shows that companies are making their cash registers ...
... have analysed the presence of voice disorders in male and ... of the Early Childhood and Primary Education teaching body suffer ... Professions such as teaching require a high resistance ... overload. "Our aim was to analyse the vocal problems of ...
Cached Medicine News:Health News:Book Delivers Latest ADHD Research, Treatments & Results 2Health News:Book Delivers Latest ADHD Research, Treatments & Results 3Health News:Confiding Eases Older Men's Stress Over Sexual Problems 2Health News:Viagra Linked to Hearing Loss 2Health News:Health Savings Account Enrollment Reaches Ten Million 2Health News:Social Media Driving Leads & Sales, New Report Shows 2Health News:More than 60 percent of teachers have voice problems 2
(Date:9/2/2014)... , Sept. 2, 2014  Ameritox SM , the ... Deadly Trend: Prescription Drugs to Heroin," a research report ... heroin abuse, and examines deadly trends that have created ... here . The report is ... patients prescribed opioids. It examines five trends that distinguish ...
(Date:9/2/2014)... September 2, 2014 ... ESC-Kongress 2014 präsentierte GARFIELD-AF-Register bietet einen ... von schlaganfallgefährdeten Patienten in der klinischen ... Daten der nahezu 12.500 ... und unabhängigen Forschungsinitiative zur Untersuchung von ...
(Date:9/2/2014)... , Registry provides new insights ... and treatment satisfaction [ 1 ] ...        (Photo: http://photos.prnewswire.com/prnh/20140902/703596 ... Barcelona, Spain : Daiichi Sankyo today ... events-European Registry in Atrial Fibrillation (PREFER in AF), revealing ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8
... CITY, Calif., April 4, 2011 Sofie Biosciences, a ... launch of GENISYS4, their new benchtop small animal PET ... Cancer Research Annual Meeting, this compact, preclinical multimodality PET ... and measure the biology of disease and therapeutic response ...
... 4, 2011 Sigma-Aldrich Corporation (Nasdaq: SIAL) ... St. Gallen, Switzerland.  The new Einstein Facility located ... home to approximately 50 employees. ... Regional Headquarters represents a critical operational milestone for ...
Cached Medicine Technology:Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology 2Sigma-Aldrich Opens European Headquarters in St. Gallen, Switzerland 2
... with built-in bags as in a suspension file ... without contacting the ethylene glycol and without having ... ensures easy handling and maximum surface freezing concurrently ... the relatively hot air under the lid does ...
... UL Listed, CSA Certified, CE ... safely store single donor, fresh ... are standard. Cold wall refrigeration ... foamed-inplace polyurethane insulation for ultimate ...
... self-contained freezer complying with Australian Standard AS3864-1997 ... finish is grey colorbond steel with a ... to a 40-litre capacity polished stainless steel ... gasket contacting a heated top fascia. A ...
... Designed for ease of use and ... has smooth edges for comfort and is ... one-size-fits-all to a perfect fit. For hard ... a trach collar to your specifications. Don't ...
Medicine Products: